Su Lwin, MRCP PhD BSc (Hons), is an academic dermatologist and Senior Research Fellow at St John’s Institute of Dermatology, King’s College London, UK. Her work sits at the intersection of rare genetic and common inflammatory skin diseases, using insights from epidermolysis bullosa (EB) and psoriasis to drive genuinely disease‑agnostic therapeutic innovation.

Su has led several landmark programmes in translational dermatology. She delivered the first fibroblast gene therapy trial for EB alongside the keratinocyte gene therapy trial for Netherton syndrome, and pioneered pre‑clinical spray‑on gene therapy for EB. Her research has also defined key regenerative and immunomodulatory mechanisms of mesenchymal stromal cell therapy in EB and psoriasis, reinforcing the critical importance of early intervention in immune‑mediated disease.

She now leads ART‑EB, the largest EB drug‑repurposing initiative aligning biologic therapies with EB immune signatures, while advancing cell‑based strategies aimed at immune retuning and long‑term reset in psoriasis